The primary cause of irAEs is the dysregulation of the immune system due to immunotherapy. Checkpoint inhibitors, for instance, target proteins that usually keep immune responses in check. By inhibiting these proteins, the drugs enable T-cells to attack cancer cells more effectively. However, this heightened immune activity can also target healthy tissues, leading to irAEs.
